| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699753 | Clinical Oncology | 2006 | 9 Pages |
Abstract
The survival probabilities at 1 and 2 years after TACE were comparable with results in randomised studies from Europe and Asia. Most patients tolerated TACE well, but clinicians need to be aware that moderately severe side-effects require close monitoring and prompt intervention.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M. Molinari, J.R. Kachura, E. Dixon, D.K. Rajan, E.B. Hayeems, M.R. Asch, M.S. Benjamin, M. Sherman, S. Gallinger, B. Burnett, R. Feld, E. Chen, P.D. Greig, D.R. Grant, J.J. Knox,